

ESKETAMINE nasal spray (Spravato® ▼) for short-term treatment of a psychiatric emergency due to Major Depressive Disorder

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ESKETAMINE nasal spray (Spravato® ▼) for short-term treatment of a psychiatric emergency due to Major Depressive Disorder.

GREY

Esketamine, co-administered with oral antidepressant therapy, is indicated in adults with a moderate to severe episode of Major Depressive Disorder (MDD), as acute short-term treatment, for the rapid reduction of depressive symptoms, which according to clinical judgement constitute a psychiatric emergency.^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of a psychiatric emergency due to MDD should continue to follow national guidance, local pathways and local formulary choices.

- > NICE CG90 [Depression in adults: recognition and management](#) (28 October 2009)
- > NICE Pathway [Depression](#) (last updated: 10 September 2020)
- > Pan Mersey APC Formulary [Antidepressant drugs](#)

References

1. Janssen-Cilag Ltd. Summary of product characteristics; [Spravato 28 mg nasal spray, solution](#), 04 February 2021. Accessed online 18 March 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.